Sanofi

Sylvette Lachaud

Jean-Christophe Carry

Laurent Schio

Michel Cheve

Francois Clerc

Cecile Combeau

Sylvie Gontier

Alain Krick

The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [&#x3b1;]D=&#x2212;38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug.

Anti-cancer compound and pharmaceutical composition containing the same

The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [&#x3b1;]D=&#x2212;38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug. 

Growing community of inventors

Paris, France

Sylvette Lachaud